ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Haemonetics Corporation (HAE) Report Updated: Jul 21, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Haemonetics Corporation (HAE)

Rating: Strong Sell Volatility: Conservative
Total Grade: F Industry: Health Care Equipment & Supplies
Competitors: SNN, KEQU, NVCN, ANIK

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: F down no change
Last Week: F same no change
Two Weeks Ago: F up no change
service keys

Haemonetics Corporation© quotemedia

Company Profile

Haemonetics Corporation develops and manufactures automated blood component collection and surgical blood salvage devices for plasma fractionators, blood collectors, and hospitals. The companyís medical device systems automate the collection and processing of donated blood components, assess likelihood for blood loss, salvage and process blood from surgery patients, and dispense and track blood inventory. Its plasma products include PCS brand plasma collection equipment and consumables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain. The companyís blood center products comprise MCS automated platelet system to collect one or more therapeutic doses of platelets during a single donation by a volunteer blood donor; SafeTrace and El Dorado Donor donation and blood unit management systems to automate and track blood center operations; Hemasphere software solution to support blood drive planning; and Donor Doc and e-Donor software to enhance recruitment and retention. Its hospital products include TEG Thrombelastograph Hemostasis Analyzer that measures patientís hemostasis and ability to form and maintain blood clots; and surgical blood salvage systems, such as Cell Saver for rapid and high-volume blood loss cardiovascular surgeries, Cell Saver Elite to minimize allogeneic blood use for medium to high blood loss surgeries, cardioPAT system for lower blood loss cardiovascular procedures, and OrthoPAT system for lower and slower blood loss orthopedic procedures. The company also provides SafeTrace TX and BloodTrack products that manage blood product inventory, patient cross-matching, and transfusion; and IMPACT Online, which monitors and measures hospitalís blood management practices. Haemonetics Corporation markets its products through direct sales force and distributors. The company was founded in 1971 and is based in Braintree, Massachusetts.

Recent News: Haemonetics Corporation